Table 1

Clinical characteristics of the three patients with systemic sclerosis and COVID-19

Patient 1Patient 2Patient 3
Age (years)718444
Body mass index (kg/m2)24.52029
Disease duration (years)4182
Cutaneous subsetDiffuseLimitedLimited
Autoantibody profileAnti-RNA polymerase 3No specific autoantibodyAnti-RNA polymerase 3
Interstitial lung diseaseNoNoNo
Pulmonary hypertensionNoNoNo
Other comorbidities
High blood pressureChronic renal insufficiencyThyroidectomy for goitre
DyslipidaemiaPulmonary embolism
 Date of the first infusion07/1701/1501/18
 Dose500 mg/6 months500 mg/8 months1 g/8 months
 Last infusion01/2006/1910/19
 B-cell depletionComplete (February 2020)Complete (February 2020)Complete (January 2020)
 Gammaglobulin (g/L)7.0 (February 2020)12.9 (February 2020)9.5 (January 2020)
Associated treatments
 csDMARDsMethotrexate (20 mg/week)NoneMethotrexate (15 mg/week)
 Prednisone (mg/day)552.5
 Day 001/04/2012/04/2015/03/20
 Confirmation by RT-PCRNot doneYesYes
 Compatible chest CT scanYesYesYes
 First symptomsFever, cough, dyspnoeaFever, diarrhoea, coughFever, cough, sore throat, myalgia
 Day of clinical worseningDay 19Day 15Day 23
 Hospitalisation in ICUYesNoYes
 Duration in hospitalisation/ICU7 daysStill in the general wardStill in the general ward
 Ventilatory supportNIVHFNCCPAP
 Other specific treatmentNoYes (anakinra, corticosteroids, tocilizumab)No
  • CPAP, continuous positive airway pressure; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; HFNC, high-flow nasal cannula; ICU, intensive care unit; NIV, non-invasive ventilation; RT-PCR, reverse transcription PCR.